Literature DB >> 3603112

Successful immunosuppressive therapy in a patient with autoantibodies to insulin receptors and immune complex glomerulonephritis.

R E Sims, F E Rushford, D P Huston, G R Cunningham.   

Abstract

Altered mental status, acanthosis nigricans, immune complex glomerulonephritis with nephrotic syndrome, fasting hypoglycemia, and postprandial hyperglycemia associated with anti-insulin receptor antibodies (type B insulin resistance) developed in a 43-year-old black woman who initially was treated for diabetes mellitus. Her HLA phenotype was A2, A29, Bw45(w6), B13(w4), Cw3, DR1 (DQw1). Her serum contained immune complexes, low complement levels, and antibodies that bound to the glomerular mesangium of mouse kidney. All clinical and serologic abnormalities resolved with combination cyclophosphamide and glucocorticoid treatment, and low doses of these agents have maintained the remission for more than a year.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3603112     DOI: 10.1097/00007611-198707000-00023

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies.

Authors:  R Malek; A Y Chong; B C Lupsa; A O Lungu; E K Cochran; M A Soos; R K Semple; J E Balow; P Gorden
Journal:  J Clin Endocrinol Metab       Date:  2010-05-19       Impact factor: 5.958

2.  Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain.

Authors:  D A Antonetti; P Algenstaedt; C R Kahn
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

3.  Saibokuto as a Possible Therapy for Type B Insulin Resistance Syndrome: The Disappearance of Anti-insulin Receptor Antibody and a Marked Amelioration of Glycemic Control by Saibokuto Treatment.

Authors:  Fumiko Kawasaki; Takatoshi Anno; Maiko Takai; Shintaro Irie; Hideaki Kaneto; Kohei Kaku; Niro Okimoto
Journal:  Intern Med       Date:  2018-03-09       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.